Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

497 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Combined ART started during acute HIV infection protects central memory CD4+ T cells and can induce remission.
Chéret A, Bacchus-Souffan C, Avettand-Fenoël V, Mélard A, Nembot G, Blanc C, Samri A, Sáez-Cirión A, Hocqueloux L, Lascoux-Combe C, Allavena C, Goujard C, Valantin MA, Leplatois A, Meyer L, Rouzioux C, Autran B; OPTIPRIM ANRS-147 Study Group. Chéret A, et al. Among authors: blanc c. J Antimicrob Chemother. 2015 Jul;70(7):2108-20. doi: 10.1093/jac/dkv084. Epub 2015 Apr 21. J Antimicrob Chemother. 2015. PMID: 25900157 Clinical Trial.
Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells.
Descours B, Avettand-Fenoel V, Blanc C, Samri A, Mélard A, Supervie V, Theodorou I, Carcelain G, Rouzioux C, Autran B; ALT ANRS CO15 Study Group. Descours B, et al. Among authors: blanc c. Clin Infect Dis. 2012 May;54(10):1495-503. doi: 10.1093/cid/cis188. Epub 2012 Mar 22. Clin Infect Dis. 2012. PMID: 22441653
A single HIV-1 cluster and a skewed immune homeostasis drive the early spread of HIV among resting CD4+ cell subsets within one month post-infection.
Bacchus C, Cheret A, Avettand-Fenoël V, Nembot G, Mélard A, Blanc C, Lascoux-Combe C, Slama L, Allegre T, Allavena C, Yazdanpanah Y, Duvivier C, Katlama C, Goujard C, Seksik BC, Leplatois A, Molina JM, Meyer L, Autran B, Rouzioux C; OPTIPRIM ANRS 147 study group. Bacchus C, et al. Among authors: blanc c. PLoS One. 2013 May 14;8(5):e64219. doi: 10.1371/journal.pone.0064219. Print 2013. PLoS One. 2013. PMID: 23691172 Free PMC article.
Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, Valantin MA, Caby F, Calin R, Lambert-Niclot S, Marcelin AG, Calvez V, Costagliola D, Katlama C. Seang S, et al. Among authors: blanc c. J Antimicrob Chemother. 2014 Dec;69(12):3356-9. doi: 10.1093/jac/dku265. Epub 2014 Jul 22. J Antimicrob Chemother. 2014. PMID: 25056835
Long-term follow-up of HIV-infected patients on dolutegravir monotherapy.
Tebano G, Soulié C, Schneider L, Blanc C, Agher R, Seang S, Valantin MA, Palich R, Tubiana R, Peytavin G, Marcelin AG, Assoumou L, Katlama C. Tebano G, et al. Among authors: blanc c. J Antimicrob Chemother. 2020 Mar 1;75(3):675-680. doi: 10.1093/jac/dkz478. J Antimicrob Chemother. 2020. PMID: 31800056
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C; ETRAL QD study group. Palich R, et al. J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423. J Antimicrob Chemother. 2021. PMID: 33099638 Clinical Trial.
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C, Reynes J, Lamaury I, Rey D, Palich R, Bani-Sadr F, Robineau O, Duvivier C, Hocqueloux L, Cuzin L, Joly V, Raffi F, Cabie A, Allavena C; Dat’AIDS Study Group. Deschanvres C, et al. J Antimicrob Chemother. 2021 Dec 24;77(1):196-204. doi: 10.1093/jac/dkab367. J Antimicrob Chemother. 2021. PMID: 34651192
497 results